Moffitt Cancer Center Market Research Report
Company Overview
- Name: Moffitt Cancer Center
- Mission: To contribute to the prevention and cure of cancer.
- Founded: No information available
- Founder(s): No information available
- Key People:
- Dr. Patrick Hwu, President and CEO
- Cathy Grant, Vice President, Chief Diversity, Equity & Inclusion Officer
- Xavier Avat, Chief Business Officer
- Headquarters: Tampa, Florida
- Number of Employees: More than 9,000 employees
- Revenue: No information available
- Known For: Moffitt Cancer Center is known for its dedication to cancer treatment, prevention, research, and education. It is recognized as a National Cancer Institute-designated Comprehensive Cancer Center and has achieved Magnet® status for nursing.
Products and Services
Cancer Treatment and Research
- Description: Moffitt Cancer Center provides comprehensive cancer treatment services including surgery, chemotherapy, radiation therapy, and clinical trials.
- Key Features:
- Multidisciplinary clinics offering personalized treatment plans
- Access to over 350 clinical trials
- Specialized programs include BMT and cellular immunotherapy, thoracic oncology, head and neck oncology
- Advanced diagnostic services such as genetic counseling and imaging
Diagnostic Services
- Description: Moffitt offers a wide range of diagnostic services aimed at early detection and precise diagnosis of various cancer types.
- Key Features:
- Comprehensive cancer screenings including lung CT and 3D mammography
- State-of-the-art imaging technology for diagnosis and surveillance
Education and Outreach
- Description: Moffitt extends its impact through education, training, and community outreach programs.
- Key Features:
- Training programs for healthcare professionals
- Community engagement to address health disparities
- Research and clinical education opportunities
Recent Developments
New Products and Initiatives
- Mobile Lung Cancer Screenings: Moffitt introduced a mobile lung cancer screening unit in Pasco County to improve early cancer detection.
- AstraZeneca Collaboration: A strategic partnership with AstraZeneca to accelerate the development of oncology cell therapies, including CAR T and TCR T therapies.
- CMIC Group Partnership: Collaborated with CMIC Group to enhance global cancer clinical trials, particularly in the Asia-Pacific region.
New Features
- Expansion of Clinical Trials: Through the collaboration with AstraZeneca and CMIC, Moffitt is broadening clinical trials to include diverse patient demographics and ensure rapid development of new therapies.
Strategic Partnerships
- CMIC Group Partnership: This partnership facilitates cross-border clinical trials and bolsters access to innovative therapies in Japan and APAC countries.
- AstraZeneca Collaboration: Enhances Moffitt’s capability to leverage AstraZeneca's investigational pipeline, focusing on cell therapies.
Conclusion
Moffitt Cancer Center is a leader in cancer treatment and research, with a robust portfolio of innovative therapies and clinical trials. Its strategic collaborations and ongoing expansions in screening and research underscore the commitment to improving cancer care and prevention on a global scale.
